When

Wednesday, October 22, 2014

11:30 AM - 1:30 PM

WheRE

Washington, DC

Congressional Hall A/B
Renaissance Washington, DC Downtown Hotel
999 Ninth St NW
Washington, DC 20001

faculty

Michael J. Brennan, MD
Interactive Professor
Director, The Pain Center of Fairfield
Fairfield, Connecticut
Senior Attending Physician
Department of Medicine, Physical Medicine, and Rehabilitation
Bridgeport Hospital
Bridgeport, Connecticut

Jeffrey A. Gudin, MD
Director
Pain Management and Wellness Center
Englewood Hospital and Medical Center
Englewood, New Jersey

Bill H. McCarberg, MD
Adjunct Assistant Clinical Professor
University of California, San Diego
Founder, Chronic Pain Management Program
Kaiser Permanente San Diego
Family Practitioner
Neighborhood Health
San Diego, California

This activity is jointly sponsored by Global Education Group and Integritas Communications.

This activity is supported by an educational grant from Teva CNS and Endo Pharmaceuticals.

Target Audience

The educational design of this activity addresses the needs of family physicians and other primary care providers involved in opioid-based management of chronic pain.

Statement of Need/Program Overview

Affecting an estimated 100 million adults in the United States, chronic pain is one of the most common reasons to seek medical treatment.1 Importantly, the associated neuroplastic changes are progressive and potentially irreversible, underscoring the need for aggressive treatment.2 Yet although relief from chronic pain is a clear medical goal, clinicians are often challenged by pain’s subjective nature and the need to balance the potential benefits and risks associated with certain medication classes. In particular, a broad analgesic spectrum and dosing flexibility have made prescription opioids the cornerstone of cancer pain treatment.3 These medications are also an important therapeutic option for carefully selected patients with moderate to severe chronic noncancer pain.4 Unfortunately, however, increased prescribing has been mirrored by growing concerns about opioid abuse and higher rates of overdose deaths.5-7 Thus, clinicians who provide opioid medications to patients with chronic pain must adopt responsible prescribing strategies, including screening for risk factors associated with aberrant drug use, appropriate monitoring, and meticulous documentation of clinical decision making.4 Other tools that can help reduce opioid-related risks for patients, prescribers, and the public include periodic urine drug testing, prescription monitoring programs, and newer long-acting opioid formulations designed to resist or deter some aberrant drug-taking behaviors.8-10 This Interactive Exchange™ program will examine each of these strategies as well as published evidence and clinical guidelines for long-term opioid therapy. The goal is to empower clinicians to select patients who may benefit from long-term opioid therapy, assess risk, monitor outcomes, and tailor opioid-based regimens over time.

References

  1. Institute of Medicine. Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research. 2011.
  2. Woolf CJ. Central sensitization: uncovering the relation between pain and plasticity. Anesthesiology. 2007;106(4):864-867.
  3. Swarm RA, Abernethy AP, Anghelescu DL, et al. Adult cancer pain. J Natl Compr Canc Netw. 2013;11(8):992-1022.
  4. Chou R, Fanciullo GJ, Fine PG, Miaskowski C, Passik SD, Portenoy RK. Opioids for chronic noncancer pain: prediction and identification of aberrant drug-related behaviors: a review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. J Pain. 2009;10(2):131-146.
  5. Starr TD, Rogak LJ, Passik SD. Substance abuse in cancer pain. Curr Pain Headache Rep. 2010;14(4):268-275.
  6. Portenoy RK. Treatment of cancer pain. Lancet. 2011;377(9784):2236-2247.
  7. Hall AJ, Logan JE, Toblin RL, et al. Patterns of abuse among unintentional pharmaceutical overdose fatalities. JAMA. 2008;300(22):2613-2620.
  8. Krashin D, Murinova N, Trescot AM. Extended-release hydrocodone - gift or curse? J Pain Res. 2013;6:53-57.
  9. Butler SF, Cassidy TA, Chilcoat H, et al. Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment. J Pain. 2013;14(4):351-358.
  10. Peppin JF, Passik SD, Couto JE, et al. Recommendations for urine drug monitoring as a component of opioid therapy in the treatment of chronic pain. Pain Med. 2012;13(7):886-896.

Educational Objectives

After completing this activity, the participant should be better able to:

  1. Discuss the neurobiologic mechanisms that underlie chronic pain and associated functional disability
  2. Assess biopsychosocial factors that contribute to chronic pain via patient histories, clinical interviews, and physical exams
  3. Tailor multimodal opioid-based therapy for patients with chronic pain based on analgesia, functional responses, adverse events, and stratified risk of aberrant behaviors
  4. Employ opioid prescribing principles for patient monitoring and documentation to comply with medical standards of care, government agencies, and risk evaluation and mitigation strategies
  5. Educate patients about the safe and appropriate use of prescription opioid analgesics, including common side effects, drug-drug interactions, and the critical need to adhere to the therapeutic plan 

Program Agenda

11:30 AM – 12:00 PM: Registration, Meal, Preactivity Outcomes Assessment

12:00 PM – 12:20 PM: Disease Management Primer

12:20 PM – 1:00 PM: Case Series in Chronic Pain

1:00 PM – 1:20 PM: Build-a-Case Collaboration

1:20 PM – 1:30 PM: Postactivity Assessment and Question and Answer Session

Physician Continuing Medical Education

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

This CME activity complies with all requirements of the federal Physician Payment Sunshine Act. If a reportable event is associated with this activity, the accredited provider managing the program will provide the appropriate physician data to the Open Payments database.

Physician Credit Designation

Global Education Group designates this live activity for a maxiumum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their partcipation in this activity. 

AAFP Credit Designation

This live activity, Caring For Patients With Chronic Pain: Responsible Opioid Prescribing To Achieve Individualized Functional Goals with a beginning date of 10/22/2014, has been reviewed and is acceptable for up to 1.5 Prescribed credit(s) by the American Academy of Family Physicians. Physicians should claim only the credit commensurate with the extent of their partcipation in this activity. 

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

For information about the accreditation of this program, please contact Global at 303-395-1782 or inquire@globaleducationgroup.com

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Integritas Communications do not recommend the use of any agent outside of the labeled indications.  

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Register Now

attend event